FTH Stock Forecast & Price Target

Faeth Therapeutics is attractive because PIKTOR is built on a biologically validated multi-node PAM blockade strategy that can suppress compensatory signaling better than single-node inhibitors, and its all-oral PI3Kα plus mTORC1/2 design may offer a practical edge over IV competitors in chronic solid-tumor settings. The most compelling near-term evidence is the 2L+ endometrial program, where early data showed an 80% ORR and 11-month mPFS in 5 patients, with differentiated tolerability marked by 14% all-grade stomatitis and no grade 3+ stomatitis, while the company models $794M in peak sales in endometrial cancer and $2.2B in worldwide peak sales in breast cancer. Management also sees a catalyst-rich path ahead, including 4Q26 topline Phase 2 endometrial data and 2027 breast cancer updates, which could de-risk a larger commercial opportunity.

Faeth Therapeutics is viewed negatively because PIKTOR’s FTH-PIK-101 phase 1b/2 breast cancer efficacy fell below Street expectations, while the company still faces classic development-stage risks of trial delays, safety issues, and regulatory setbacks. The bear case assumes PIKTOR may not show compelling efficacy or tolerability, which could push POS down to 15% in endometrial cancer and 10% in mBC, implying roughly 30% downside to the Base Case. The competitive backdrop is also worsening, with strong gedatolisib momentum, other PI3Kα programs showing better efficacy/safety, and persistent toxicity concerns across the pathway leaving Faeth with a likely need for additional capital if clinical or commercial progress disappoints.